ACM
STOK icon

ADAR1 Capital Management’s Stoke Therapeutics STOK Stock Holding History

ADAR1 Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,285
Closed -$310K – 259
2025
Q2 		$310K Sell
27,285
-2,800
-9% -$26.6K 0.05% 137
2025
Q1 		$200K Buy
+30,085
New +$280K 0.04% 146
2024
Q2 		– Sell
-2,900
Closed -$39.1K – 312
2024
Q1 		$39.1K Buy
+2,900
New +$17.6K 0.01% 194

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

ADAR1 Capital Management's STOK Position: Q3 2025 in Review

ADAR1 Capital Management sold out of Stoke Therapeutics (STOK) in Q3 2025, closing a stake of 27,285 shares — an estimated $310K sold.

ADAR1 Capital Management first reported a position in STOK in Q1 2024 and held it in 3 quarters. The position peaked at $310K in Q2 2025. 151 funds tracked by Wall St. Rank hold STOK as of Q3 2025.

  • ADAR1 Capital Management reported no remaining Stoke Therapeutics position as of Q3 2025 after selling out during the quarter.
  • ADAR1 Capital Management sold 27,285 Stoke Therapeutics shares in Q3 2025, an estimated $310K.
  • ADAR1 Capital Management first reported a position in Stoke Therapeutics in Q1 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's Stoke Therapeutics position peaked at $310K in Q2 2025.
  • 151 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2025.

Based on ADAR1 Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.